Restructured Melinta now wants to buy fellow antibiotic maker Tetraphase; TA Associates mulls $500M deal for a stake in CDMO
→ Yet another buyer has emerged in what is shaping up to be a bidding war for Tetraphase and its marketed antibiotic. Melinta — a fellow antibiotics maker that’s freshly restructured under Chapter 11 and now privately owned by Deerfield — is offering to buy it all for $27 million, more than double the original offer by AcelRx that the Tetraphase board had recommended back in March. Since then, La Jolla has also proposed a $22 million deal.
Tetraphase now considers the Melinta offer superior to AcelRx’s and might change its mind, it said, unless AcelRx revises its terms by next Friday.
→ Boston-based TA Associates is in talks to buy a 20% stake in an Indian contract development and manufacturing organization, Bloomberg reported. The private equity firm might spend up to $500 million to grab a piece of Piramal Pharma, according to sources, which also said KKR & Co was competing for the stake earlier.